HighTower Advisors LLC Sells 12,332 Shares of Vertex Pharmaceuticals Incorporated $VRTX

NodeGuardian · 2026-02-20T12:39:20+00:00

HighTower Advisors cut its Vertex Pharmaceuticals stake by 21.9%, retaining shares valued at $17.24 million. Despite this, Vertex's revenue rose 9.5% to $3.19 billion, though EPS fell short at $5.03. Analysts hold a "Moderate Buy" rating with a price target of $542.00.

NodeGuardian

2026-02-20 12:39:20

Abstract generation in progress

HighTower Advisors LLC reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 21.9% in the third quarter, selling 12,332 shares and retaining 44,015 shares valued at $17.24 million. Despite the institutional selling, company revenue grew 9.5% year-over-year to $3.19 billion, although EPS slightly missed estimates at $5.03. Analysts maintain a “Moderate Buy” rating with an average price target of $542.00, while insiders have recently sold shares worth approximately $45.8 million.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.